Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

WILLS AND ESTATES Help Canadians Affected by Osteoporosis by Leaving a Gift in Your Will When you leave a gift to Osteoporosis Canada in your Will, you can feel confident […]

On September 29, 2015, two research articles were published online in the British Medical Journal (BMJ) concerning the effect of calcium intake on bone mineral density (BMD) and fracture reduction. […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Osteoporosis Canada is pleased to announce that effective November 1, 2023 Dr. Sonia Singh will be joining the organization as the new OC National FLS Implementation Lead, previously known as […]

IMPACT REPORT 2018 – 2019 PATIENT STORY: MEET BRUCE SCAFE On the day after Bruce’s 60th birthday, he ran his very first marathon. It was months of training for the […]